Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial. - Abraham JE; O'Connor LO; Grybowicz L; Alba KP; Dayimu A; Demiris N; Harvey C; Drewett LM; Lucey R; Fulton A; Roberts AN; Worley JR; et al. (Nature communications, 2025)